Item 8.01 Other Events.

On September 16, 2021, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing the enrollment of the first patient in the Company's SYMPHONY (Study Evaluating a Mechanistic Approach to Treating Narcolepsy) Phase 3 trial of AXS-12 (reboxetine) in narcolepsy.

The full text of the press release is filed as Exhibit 99.1 hereto, and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit No.                                  Description

99.1                Press Release dated September 16, 2021.

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document).




                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses